Tectonic Therapeutic

About Tectonic Therapeutic

Tectonic Therapeutic is a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate G-Protein Coupled Receptors (GPCRs). Co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, Tectonic uses its proprietary GEODe™ platform to address significant unmet medical needs and develop novel GPCR-targeted biologic medicines to improve patient quality of life.

Products & Services

Relaxin (TX45):A long-acting Fc-relaxin fusion protein targeting Group 2 Pulmonary Hypertension (PH) and Hereditary Hemorrhagic Telangiectasia (HHT), aimed at addressing large, unmet need diseases.

Specialties

G-Protein Coupled Receptors (GPCRs) Therapeutic Proteins Antibodies Biologic Medicines GEODe™ Platform

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement (PIPE) T: - FT: Private Placement (PIPE)	A: 185000000 MR: - FA: approximately $185.0 million FAN: 185000000	D: 2025-02-03 FD: 2025-02-03	12 investors

Private Placement (PIPE) Latest

2025-02-03

$185.0M

12 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alise Reicin

President and CEO, Director

J

John Diener

Senior Vice President, Antibody Engineering & Protein Sciences

D

Daniel Lochner

Chief Financial Officer

P

Peter McNamara

Chief Scientific Officer

A

Anthony Muslin

Chief Development Officer

M

Marcella K Ruddy

Chief Medical Officer

View 10 more team members with Pro

Unlock Full Team Directory

Recent News